Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Kumari Chandrawansa | Researchclopedia

Back to researchers

Kumari Chandrawansa

Bayer (United States)

33

Works

3,431

Citations

15

h-index

17

i10-index

Research Topics

Gastric Cancer Management and Outcomes Colorectal Cancer Treatments and Studies Esophageal Cancer Research and Treatment

Affiliations

Roswell Park Comprehensive Cancer Center2010–2010

Bayer (United States)2016–2023

Oregon Health & Science University2009–2009

Eli Lilly (United States)2014–2017

University of California, San Francisco2009–2009

Top Works

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

H. Wilke,Kei Muro,et al.

20142,435 citations

Gastrointestinal Tumor Research and Treatment

Helicobacter pylori-related gastroenterology studies

Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Linda T. Vahdat,Brian Pruitt,et al.

2009245 citations

Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer

Diane Reidy‐Lagunes,Efsevia Vakiani,et al.

2010139 citations

RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE).

H. Wilke,Eric Van Cutsem,et al.

201492 citations

Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer

Kohei Shitara,Kei Muro,et al.

201585 citations

Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma

Salah‐Eddin Al‐Batran,Eric Van Cutsem,et al.

201676 citations

Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data

Charles S. Fuchs,Kei Muro,et al.

201771 citations

Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer

Josep Tabernero,Atsushi Ohtsu,et al.

201748 citations

Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer

Kei Muro,Sang Cheul Oh,et al.

201540 citations